CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Open-market sale SVP, Product Development & CTO sold 5,922 shares at $50.00 ($296,100)
- 4 Open-market sale Chief Financial Officer sold 2,394 shares at $50.00 ($119,700)
- 4 Open-market sale Director sold 3,200 shares at $50.01 ($160,032)
- 4 Open-market sale Director sold 30,000 shares at $45.60 ($1,368,000)
- 4 Open-market sale Chief Financial Officer sold 7,500 shares at an average $41.75 ($313,152)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale SVP, Product Development & CTO sold 15,552 shares at an average $43.74 ($680,248)
- 4 Open-market sale President and CEO sold 10,000 shares at an average $39.75 ($397,497)
- 4 Open-market sale SVP, General Counsel sold 5,486 shares at $42.00 ($230,412)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $37.55 ($563,243)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $49.49 ($742,311)
- 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $50.03 ($250,147)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $52.54 ($788,088)
- 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $52.99 ($264,965)
- 4 Derivatives Options or other derivatives
Page 11 of 22 · 435 filings